RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...
Nasdaq

Immuron Limited Submits Phase 2 Clinical Study Report for Travelan® (IMM-124E) to FDA, Achieving Significant Immunology and Microbiome Results

Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...